Diagnostic Approach for Breast Nodules

Introduction to Breast Nodule Diagnosis

Breast nodules require systematic evaluation through the diagnostic triad of clinical examination, bilateral mammography with ultrasound, and pathological assessment via core needle biopsy to distinguish between benign and malignant etiologies 1, 2, 3

Invasive ductal carcinoma represents the most common malignancy, requiring full pathological assessment including ER, PR, and HER2 status 1, 2, 3
Invasive lobular carcinoma can present with subtle imaging findings and requires careful evaluation 4
Ductal carcinoma in situ (DCIS) may present as asymmetry without calcifications, particularly low and intermediate-grade DCIS 4

Large tumors ≥5 cm indicate locally advanced disease requiring comprehensive staging with chest CT, abdominal imaging, and bone scan 5
Clinically positive axillary lymph nodes mandate full staging investigations and indicate higher metastatic risk 5
High histological grade tumors demonstrate aggressive behavior requiring systemic therapy 5
Peritumoral vascular invasion indicates increased metastatic spread risk 5

Clinical examination should assess for palpable mass characteristics, asymmetric thickening/nodularity, nipple discharge, and skin changes including peau d'orange, erythema, or nipple excoriation 6
Bilateral mammography is mandatory to evaluate for occult or multifocal disease, even when a dominant mass is present 1, 2
Targeted ultrasound must be performed concurrently to identify potentially benign causes and provide biopsy targets, with sensitivity reaching 93-100% when combined with other modalities 4

Core needle biopsy (preferred) or fine needle aspiration should be obtained before any surgical procedure, with core biopsy providing superior histological architecture assessment 1, 2, 3
Final pathological diagnosis must follow WHO classification and TNM staging, including ER, PR, and HER2 status determination 1, 2, 3

BI-RADS 4-5 lesions require immediate tissue diagnosis via image-guided core needle biopsy 6, 4
Developing asymmetry carries 12.8% cancer risk at screening and 42.9% when biopsy is recommended, with 23.8% having no sonographic correlate 4
Any suspicious features including architectural distortion, associated microcalcifications, palpable abnormality, or new/increasing size mandate biopsy regardless of other benign features 4